Holen Sie sich die Stockscreener-App
9.28
2.26%
-0.215
Vorhandelsmarkt:
9.38
0.10
+1.08%
Schlusskurs vom Vortag:
$9.495
Offen:
$9.69
24-Stunden-Volumen:
734.88K
Relative Volume:
1.56
Marktkapitalisierung:
$628.70M
Einnahmen:
$568.09M
Nettoeinkommen (Verlust:
$27.27M
KGV:
28.33
EPS:
0.3276
Netto-Cashflow:
$71.41M
1W Leistung:
-12.29%
1M Leistung:
-5.02%
6M Leistung:
+28.18%
1J Leistung:
+42.55%
1-Tages-Spanne:
$9.185
$9.76
1-Wochen-Bereich:
$9.185
$11.00
52-Wochen-Spanne:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.28 | 643.27M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | CJS Securities | Market Outperform |
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BVS Maintained by Barrington Research -- Price Target at $14.00 - GuruFocus
Bioventus Inc.Class A Common Stock (NQ: BVS - The Chronicle-Journal
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga
Bioventus Is Maintained at Outperform by Barrington Research - Moomoo
Bioventus Inc. Files Form 8-K: Corporate Details, Stock Information, and SEC Compliance for May 2026 - Minichart
FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook - Investing.com UK
FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook By Investing.com - Investing.com South Africa
Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027. - Bitget
GE Vernova Inc. announces the acquisition of Robotech Automation to accelerate advancements in its robotics and automation capabilities. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission, the U.S. Food and Drug Administration completed the reclassification of Bioventus Inc.'s Exogen ultrasound bone healing system on April 16, 2026. - Bitget
FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged - TradingView
CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact - Stock Titan
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
(BVS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bioventus (BVS) Q1 2026 Earnings: EPS $0.15 Beats EstimatesHot Community Stocks - Newser
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are - Sahm
Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com
Wall Street analysts see a 38.97% upside in Bioventus (BVS): Can the stock really move this high? - MSN
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High? - Yahoo Finance
Bioventus Inc. (BVS) Stock Analysis: Unpacking a 38.97% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Bioventus (BVS) Raises FY26 Financial Guidance Following Strong Performance - GuruFocus
Bioventus (BVS) Reports Strong Q1 Revenue Growth - GuruFocus
Barrington Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Q1 2026 Bioventus Inc Earnings Call Transcript - GuruFocus
Bioventus Inc. (NASDAQ:BVS) Q1 2026 Earnings Call Transcript - Insider Monkey
Bioventus Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Australia
Bioventus: Q1 Earnings Snapshot - theheraldreview.com
Bioventus Earnings Call Highlights Growth, Cash Strength - TipRanks
Is Bioventus Healthcare Momentum Lifting Nasdaq ETF Attention? - Kalkine Media
Bioventus Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue - MSN
Bioventus (BVS) surpasses Q1 earnings and revenue estimates - MSN
Bioventus Inc. Q1 2026 Financial Results: Earnings, Risk Factors, and Market Outlook - Minichart
Bioventus Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-05-06 - Seeking Alpha
Bioventus (NASDAQ:BVS) Reaches New 1-Year High on Better-Than-Expected Earnings - MarketBeat
Price-Driven Insight from (BVS) for Rule-Based Strategy - Stock Traders Daily
Bioventus Q1 Earnings Call Highlights - MarketBeat
Bioventus Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Bioventus Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026 - marketscreener.com
Earnings call transcript: Bioventus beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Australia
Earnings call transcript: Bioventus beats Q1 2026 forecasts, stock rises - Investing.com
Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Bioventus : Q1'26 Earnings Call Slides - marketscreener.com
Bioventus Inc (NASDAQ:BVS) Smashes Q1 Estimates and Lifts Guidance, Shares Rally - ChartMill
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):